Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia

Biological Psychiatry

Volumn 46, Issue 12, 1999, Pages 1698-1702

  Landén, Mikael ^a,d   Davidsson, Pia ^a   Gottfries, Carl Gerhard ^a   Grenfeldt, Bengt ^a   Stridsberg, Mats ^b   Blennow, Kaj ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL RESEARCH COUNCIL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chromogranins; Schizophrenia; Synapse; Synaptophysin; Thalamus

Indexed keywords

CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; SECRETOGRANIN II; SYNAPTOPHYSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NERVE ENDING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; THALAMUS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CHROMOGRANINS; DOMINANCE, CEREBRAL; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; SYNAPTOPHYSIN; THALAMUS;

EID: 0033406678     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00160-2     Document Type: Article

References (45)

1. Adolfsson R, Gottfries CG, Nyström L, Winblad B (1981): Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand 63:225-244.
2. Alford MF, Masliah E, Hansen LA, Terry RD (1994): A simple dot-immunobinding assay for quantification of synaptophysin-like immunoreactivity in human brain. J Histochem Cytochem 42:283-237.
3. Anderson J, Fawdry R, Gordon E, Coyle S, Gruenewald S, Meares RA (1991): SPECT asymmetry of left temporal lobe in hallucinating schizophrenics of the indifferentiated type. Biol Psychiatry 29:2918.
4. Andreasen NC (1995): Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477-481.
5. Andreasen NC (1997): The role of the thalamus in schizophrenia [see comments]. Can J Psychiatry 42:27-33.
6. Andreasen NC, Arndt S, Swayze V II, et al (1994): Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging [see comments]. Science 266: 294-298.
7. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE (1990): Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147:1457-1462.
8. Benes FM (1993): Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophr Bull 19:537-549.
9. Blennow K, Davidsson P, Gottfries CG, Ekman R, Heilig M (1996): Synaptic degeneration in thalamus in schizophrenia [letter]. Lancet 348:692-693.
10. Brown S (1997): Excess mortality of schizophrenia - A meta-analysis. Br J Psychiatry 171:502-508.
11. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R (1993): Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry 34:529-535.
12. Buchsbaum MS, Someya T, Teng CY, et al (1996): PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 153:191-199.
13. Cleghorn JM, Garnett ES, Nahmias C, et al (1990): Regional brain metabolism during auditory hallucinations in chronic schizophrenia. Br J Psychiatry 157:562-570.
14. DeLisi LE, Buchsbaum MS, Holcomb HH, et al (1989): Increased temporal lobe glucose use in chronic schizophrenic patients. Biol Psychiatry 25:835-851.
15. Early TS, Reiman EM, Raichle ME, Spitznagel EL (1987): Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA 84:561-563.
16. Eastwood SL, Burnet PW, Harrison PJ (1995): Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66:309-319.
17. Eastwood SL, Harrison PJ (1995): Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience 69:339-343.
18. Eastwood SL, Heffernan J, Harrison PJ (1997): Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol Psychiatry 2:322-329.
19. Fischer Colbrie R, Hagn C, Schober M (1987): Chromogranins A, B, and C: Widespread constituents of secretory vesicles. Ann NY Acad Sci 493:120-134.
20. Fischer von Mollard G, Mignery GA, Baumert M, et al (1990): rab3 is a small GTP-binding protein exclusively localized to synaptic vesicles. Proc Natl Acad Sci USA 87:1988-1992.
21. Gabriel SM, Haroutunian V, Powchik P, et al (1997): Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia [published erratum appears in Arch Gen Psychiatry 1997 54:912]. Arch Gen Psychiatry 54:559-566.
22. Glantz LA, Lewis DA (1997): Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: Regional and diagnostic specificity. Arch Gen Psychiatry 54:943-952.
23. Gur RE (1978): Left hemisphere dysfunction and left hemisphere overactivation in schizophrenia. J Abnorm Psychol 87:226-238.
24. Gur RE, Resnick SM, Gur RC (1989): Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity. Psychiatry Res 27:325-334.
25. Gur RE, Resnick SM, Gur RC, et al (1987): Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch Gen Psychiatry 44:126-129.
26. Hamos JE, DeGennaro LJ, Drachman DA (1989): Synaptic loss in Alzheimer's disease and other dementias. Neurology 39: 355-361.
27. Jones EG (1997): Cortical development and thalamic pathology in schizophrenia [see comments]. Schizophr Bull 23:483-501.
28. Kane JM, McGlashan TH (1995): Treatment of schizophrenia. Lancet 346:820-825.
29. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS (1999): Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality.' Mol Psychiatry 4:39-45.
30. Knapp M (1997): Costs of schizophrenia. Br J Psych 171:509-518.
31. Manaye KF, German DC, Liang CL, Hicks PB, Young KA (1997): Reduced number of mediodorsal thalamic neurons in schizophrenia. Soc Neurosci Abstr 23:854.13.
32. Masliah E, Terry RD, Alford M, DeTeresa R (1990): Quantitative immunohistochemistry of synaptophysin in human neocortex: An alternative method to estimate density of presyn-aptic terminals in paraffin sections. J Histochem Cytochem 38:837-844.
33. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA (1998): The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59:69-75.
34. Munoz DG, Kobylinski L, Henry DD, George DH (1990): Chromogranin A-like immunoreactivity in the human brain: Distribution in bulbar medulla and cerebral cortex. Neuroscience 34:533-543.
35. Pakkenberg B (1992): Stereological quantitation of human brains from normal and schizophrenic individuals. Acta Neurol Scand Suppl 137:20-33.
36. Perrone Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL (1996): Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci USA 93:14182-14187.
37. Reynolds GP (1983): Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527-529.
38. Rossi A, Stratta P, D'Albenzio L, et al (1990): Reduced temporal lobe areas in schizophrenia: Preliminary evidences from a controlled multiplanar magnetic resonance imaging study. Biol Psychiatry 27:61-68.
39. Shenton ME, Kikinis R, Jolesz FA, et al (1992): Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med 327:604-612.
40. Somogyi P, Hodgson AJ, DePotter RW, et al (1984): Chromogranin immunoreactivity in the central nervous system. Immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways. Brain Res 320:193-230.
41. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K (1993): Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 139:329-337.
42. Stridsberg M, Lundqvist G, Engstrom U, et al (1994): Development of polyclonal antibodies and evaluation of a sensitive radioimmunoassay for detection and measurement of synaptophysin. Acta Neuropathol 87:635-641.
43. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G (1995): Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144:49-59.
44. Wiedenmann B, Franke WW (1985): Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 41: 1017-1028.
45. Williamson P, Pelz D, Merskey H, Morrison S, Conlon P (1991): Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging. Br J Psychiatry 159:130-134.